Equity Components [Axis]
Common Stock [Member]
Preferred Stock [Member]
Additional Paid-in Capital [Member]
Retained Earnings [Member]
Award Type [Axis]
Senior Notes Due 2031 Notes [Member]
Long-Lived Tangible Asset [Axis]
Furniture and Fixtures [Member]
Antidilutive Securities [Axis]
Options To Purchase Common Stock [Member]
Convertible notes to common stock [Member]
Warrants To Purchase Common Stock [Member]
Restricted Stock [Member]
Preferred Stock On An As If Converted To Common Stock [Member]
Statistical Measurement [Axis]
Maximum [Member]
Financial Instrument [Axis]
US Treasury Securities [Member]
Leasehold Improvements [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Axis]
Securities Purchase Agreement [Member]
Class of Stock [Axis]
Series A Preferred Stock [Member]
Underwriting Agreement [Member]
July 2025 Equity Offering [Member]
Class of Warrant or Right [Axis]
Pre-Funded Warrants [Member]
Related and Nonrelated Parties [Axis]
Leerink Partners LLC [Member]
Open Market Sale Agreement [Member]
Legal Entity [Axis]
Jefferies LLC [Member]
Warrant [Member]
Minimum [Member]
Warrant One [Member]
Warrant Two [Member]
Warrant Three [Member]
Warrant Four [Member]
Warrant Five [Member]
Warrant Six [Member]
Warrant Seven [Member]
Warrant Eight [Member]
Warrant Nine [Member]
Warrant Ten [Member]
Warrant Eleven [Member]
Plan Name [Axis]
2012 Equity Incentive Plan [Member]
2017 Amended And Restated Stock Incentive Plan [Member]
2017 Plan [Member]
Equity Option [Member]
Share-Based Payment Arrangement, Option [Member]
2017 Employee Stock Purchase Plan [Member]
Statement of Income Location Balance [Axis]
Research and Development Expenses [Member]
General and Administrative Expenses [Member]
Note Underwriting Agreement [Member]
July 2025 Convertible Notes Offering [Member]
Sale of Stock [Axis]
Over-Allotment Option [Member]
Subsequent Event Type [Axis]
Subsequent Event [Member]
Amended and Restated Loan Agreement [Member]
Innovatus Life Sciences [Member]
Debt Instrument [Axis]
Term D Loan [Member]
Term E Loan [Member]
Term E Two Loan [Member]
Term F Loan [Member]
Term F Two Loan [Member]
Term G Loan [Member]
Third Amendment to Amended and Restated Loan and Security Agreement [Member]
Second Amendment To Amended And Restated Loan And Security Agreement [Member]
Loan Agreement [Member]
Term A Loan [Member]
Term B Loan [Member]
Term C Loan [Member]
Prior Loan Agreement [Member]
Pfizer License Agreement [Member]
License Agreement [Member]
Income Tax Jurisdiction [Axis]
Domestic Tax Jurisdiction [Member]
State and Local Jurisdiction [Member]
Cover [Abstract]
Document Type
Amendment Flag
Amendment Description
Document Registration Statement
Document Annual Report
Document Quarterly Report
Document Transition Report
Document Shell Company Report
Document Shell Company Event Date
Document Period Start Date
Document Period End Date
Document Fiscal Period Focus
Document Fiscal Year Focus
Current Fiscal Year End Date
Entity File Number
Entity Registrant Name
Entity Central Index Key
Entity Primary SIC Number
Entity Tax Identification Number
Entity Incorporation, State or Country Code
Entity Address, Address Line One
Entity Address, Address Line Two
Entity Address, Address Line Three
Entity Address, City or Town
Entity Address, State or Province
Entity Address, Country
Entity Address, Postal Zip Code
Country Region
City Area Code
Local Phone Number
Extension
Written Communications
Soliciting Material
Pre-commencement Tender Offer
Pre-commencement Issuer Tender Offer
Title of 12(b) Security
No Trading Symbol Flag
Trading Symbol
Security Exchange Name
Title of 12(g) Security
Security Reporting Obligation
Annual Information Form
Audited Annual Financial Statements
Entity Well-known Seasoned Issuer
Entity Voluntary Filers
Entity Current Reporting Status
Entity Interactive Data Current
Entity Filer Category
Entity Small Business
Entity Emerging Growth Company
Elected Not To Use the Extended Transition Period
Document Accounting Standard
Other Reporting Standard Item Number
Entity Shell Company
Entity Public Float
Entity Bankruptcy Proceedings, Reporting Current
Entity Common Stock, Shares Outstanding
Documents Incorporated by Reference [Text Block]
ICFR Auditor Attestation Flag
Document Financial Statement Error Correction [Flag]
Auditor Opinion [Text Block]
Auditor Name
Auditor Location
Auditor Firm ID
Statement of Financial Position [Abstract]
Assets
Current assets:
Cash and cash equivalents
Investments
Prepaid clinical trial costs
Other current assets
Total current assets
Property and equipment, net
Operating lease right-of-use assets
Other non-current assets
Total assets
Liabilities and stockholders’ equity
Current liabilities:
Accounts payable
Accrued clinical trial costs
Other accrued expenses
Operating lease liabilities, current
Total current liabilities
Operating lease liabilities, non-current
Convertible debt
Note payable, non-current
Total liabilities
Commitments and contingencies (Note 7)
Stockholders’ equity:
Preferred stock, $0.001 par value: 2,500,000 shares authorized as of December 31, 2025 and 2024; 0 and 317,577 shares issued and outstanding as of December 31, 2025 and 2024, respectively
Common stock, $0.001 par value: 95,000,000 shares authorized as of December 31, 2025 and 2024; 48,244,960 and 37,143,242 shares issued and outstanding as of December 31, 2025 and 2024, respectively
Additional paid-in capital
Accumulated deficit
Total stockholders’ equity
Total liabilities and stockholders’ equity
Preferred stock, par value
Preferred stock, shares authorized
Preferred stock, shares issued
Preferred stock, shares outstanding
Common stock, par value
Common stock, shares authorized
Common stock, shares issued
Common stock, shares outstanding
Income Statement [Abstract]
Operating expenses:
Research and development
General and administrative
Total operating expenses
Loss from operations
Other (expense) income:
Interest expense
Interest income
Other (expense) income, net
Net loss before income taxes
Income taxes
Net loss
Net loss per share, basic
Net loss per share, diluted
Weighted average common shares outstanding, basic
Weighted average common shares outstanding, diluted
Statement [Table]
Statement [Line Items]
Balance
Balance, shares
Stock-based compensation
Stock-based compensation, shares
Conversion of preferred stock to common stock
Conversion of preferred stock to common stock, shares
Employee stock purchases
Employee stock purchases, shares
Exercise of common stock options, net of shares withheld for exercise price
Exercise of common stock options, net of shares withheld for exercise price, shares
Exercise of common stock warrants, net of shares withheld for exercise price
Exercise of common stock warrants, net of shares withheld for exercise price, shares
Issuance of common stock in an ATM offering, net of issuance costs
Issuance of common stock in an ATM offering, net of issuance costs, shares
Issuance of common stock upon closing of equity offering, net of underwriting discounts and offering costs
Issuance of common stock upon closing of equity offering, net of underwriting discounts and offering costs, shares
Issuance of common stock warrants, note payable
Net loss
Issuance of common stock warrants in connection with note agreement
Balance
Balance, shares
Statement of Cash Flows [Abstract]
Cash flows from operating activities:
Adjustments to reconcile net loss to net cash and cash equivalents used in operations:
Depreciation
Stock-based compensation
Amortization of debt issuance costs and discount
Payment-in-kind interest
Non-cash operating lease expense
Change in accrued interest income
Changes in operating assets and liabilities:
Prepaid clinical trial costs
Other current and non-current assets
Accounts payable
Accrued clinical trial costs
Other accrued expenses
Net cash used in operating activities
Cash flows from investing activities:
Proceeds from maturities of investments
Purchases of investments
Purchases of property and equipment
Net cash used in investing activities
Cash flows from financing activities:
Proceeds from employee stock purchases
Proceeds from exercise of common stock options
Proceeds from exercise of common stock warrants
Proceeds from convertible debt, net of debt issuance costs of $6,246 and $0 during the years ended December 31, 2025 and 2024, respectively
Proceeds from note payable, net of debt issuance costs of $2,255 and $2,438 during the years ended December 31, 2025 and 2024, respectively
Proceeds from equity offering, net of underwriting discounts and offering costs
Proceeds from an ATM offering, net of issuance costs
Payments for secondary registration statement costs
Net cash provided by financing activities
Net change in cash and cash equivalents
Cash and cash equivalents:
Beginning of period
End of period
Supplemental disclosure of cash flow information:
Cash paid for interest
Cash paid for operating leases
Supplemental disclosures of non-cash investing and financing activities:
Common stock warrants issued with the note payable transaction
Property and equipment included in accounts payable
Deferred financing, offering and registration statement costs included in accounts payable
Proceeds from convertible note payable, net of debt issuance cost and discount
Debt issuance costs and discount
Pay vs Performance Disclosure [Table]
Executive Category [Axis]
Individual [Axis]
Adjustment to Compensation [Axis]
Measure [Axis]
Pay vs Performance Disclosure, Table
Company Selected Measure Name
Named Executive Officers, Footnote
Peer Group Issuers, Footnote
Changed Peer Group, Footnote
PEO Total Compensation Amount
PEO Actually Paid Compensation Amount
Adjustment To PEO Compensation, Footnote
Non-PEO NEO Average Total Compensation Amount
Non-PEO NEO Average Compensation Actually Paid Amount
Adjustment to Non-PEO NEO Compensation Footnote
Equity Valuation Assumption Difference, Footnote
Compensation Actually Paid vs. Total Shareholder Return
Compensation Actually Paid vs. Net Income
Compensation Actually Paid vs. Company Selected Measure
Total Shareholder Return Vs Peer Group
Compensation Actually Paid vs. Other Measure
Tabular List, Table
Total Shareholder Return Amount
Peer Group Total Shareholder Return Amount
Net Income (Loss)
Company Selected Measure Amount
Other Performance Measure, Amount
Adjustment to Compensation, Amount
PEO Name
Name
Non-GAAP Measure Description
Additional 402(v) Disclosure
Pension Benefits Adjustments, Footnote
Equity Awards Adjustments, Footnote
Erroneously Awarded Compensation Recovery [Table]
Restatement Determination Date [Axis]
Restatement Determination Date
Aggregate Erroneous Compensation Amount
Erroneous Compensation Analysis
Stock Price or TSR Estimation Method
Outstanding Aggregate Erroneous Compensation Amount
Aggregate Erroneous Compensation Not Yet Determined
Name
Forgone Recovery due to Expense of Enforcement, Amount
Forgone Recovery due to Violation of Home Country Law, Amount
Forgone Recovery due to Disqualification of Tax Benefits, Amount
Forgone Recovery, Explanation of Impracticability
Name
Compensation Amount
Restatement does not require Recovery
Awards Close in Time to MNPI Disclosures [Table]
Award Timing MNPI Disclosure
Award Timing Method
Award Timing Predetermined
Award Timing MNPI Considered
Award Timing, How MNPI Considered
MNPI Disclosure Timed for Compensation Value
Awards Close in Time to MNPI Disclosures, Table
Name
Underlying Securities
Exercise Price
Fair Value as of Grant Date
Underlying Security Market Price Change
Insider Trading Arrangements [Line Items]
Material Terms of Trading Arrangement
Name
Title
Rule 10b51 Arrangement Adopted
Non-Rule 10b5-1 Arrangement Adopted
Adoption Date
Rule 10b51 Arrangement Adopted
Rule 10b51 Arrangement Adopted
Termination Date
Expiration Date
Arrangement Duration
Aggregate Available
Insider Trading Policies and Procedures [Line Items]
Insider Trading Policies and Procedures Adopted
Insider Trading Policies and Procedures Not Adopted
Cybersecurity Risk Management, Strategy, and Governance [Abstract]
Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]
Cybersecurity Risk Management Processes Integrated [Flag]
Cybersecurity Risk Management Processes Integrated [Text Block]
Cybersecurity Risk Management Third Party Engaged [Flag]
Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]
Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]
Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]
Cybersecurity Risk Board of Directors Oversight [Text Block]
Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]
Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]
Cybersecurity Risk Role of Management [Text Block]
Cybersecurity Risk Management Positions or Committees Responsible [Flag]
Cybersecurity Risk Management Positions or Committees Responsible [Text Block]
Cybersecurity Risk Management Expertise of Management Responsible [Text Block]
Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]
Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]
Material Cybersecurity Incident [Abstract]
Material Cybersecurity Incident Nature [Text Block]
Material Cybersecurity Incident Scope [Text Block]
Material Cybersecurity Incident Timing [Text Block]
Material Cybersecurity Incident Material Impact or Reasonably Likely Material Impact [Text Block]
Material Cybersecurity Incident Information Not Available or Undetermined [Text Block]
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and Liquidity
Accounting Policies [Abstract]
Basis of Presentation and Summary of Significant Accounting Policies
Earnings Per Share [Abstract]
Net Loss Per Common Share
Investments, All Other Investments [Abstract]
Investments
Property, Plant and Equipment [Abstract]
Property and Equipment
Payables and Accruals [Abstract]
Other Accrued Expenses
Commitments and Contingencies Disclosure [Abstract]
Commitments
Equity [Abstract]
Stockholders’ Equity
Share-Based Payment Arrangement [Abstract]
Stock-Based Compensation
Debt Disclosure [Abstract]
Debt
License Agreement
License Agreement
Income Tax Disclosure [Abstract]
Income Taxes
Subsequent Events [Abstract]
Subsequent Events
Basis of Presentation
Accounting Estimates
Cash and Cash Equivalents
Investments
Fair Value of Financial Instruments
Concentration of Credit Risk
Allowance for Credit Losses
Property and Equipment
Leases
Capitalized Software Development Costs
Long-Lived Assets
Deferred Transaction Costs
Debt Issuance Costs
Comprehensive Loss
Commitments and Contingencies
Stock-Based Compensation
Research and Development
Clinical Trial Costs
Licenses
Patent Costs
Income Taxes
Segment Data
Recently Adopted Accounting Pronouncements
Recent Accounting Pronouncements Not Yet Adopted
Schedule of Estimated Useful Lives of Property and Equipment
Schedule of Potentially-Dilutive Shares Excluded from Diluted Weighted-Average Shares Outstanding
Schedule of Investment
Summary of Property and Equipment
Schedule of Other Accrued Expenses
Schedule of Minimum Lease Payments
Schedule of Lease Costs
Schedule of Common Stock Warrants
Schedule of Common Stock Warrants Outstanding
Schedule of Stock Options Activity
Schedule of Assumptions for Fair Value of Employee And Non-Employee Stock Option
Schedule of Restricted Stock Award And Restricted Stock Unit Activity
Schedule of Stock-based Compensation Expenses
Schedule of Long-term Debt
Schedule of Long Term Debt Future Principal Payments
Schedule of Effective Income Tax Rate Reconciliation
Schedule of Deferred Tax Assets and Liabilities
Accumulated deficit
Cash and cash equivalents
Property, Plant and Equipment [Table]
Property, Plant and Equipment [Line Items]
Estimated useful lives
Property, Plant, and Equipment, Useful Life, Term, Description [Extensible Enumeration]
Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Short-term investments
Accrue interest payable rate
Capitalized software development costs
Deferred transaction costs
Research and development expense
Number of operating segment
Number of reportable segment
Antidilutive Security, Excluded EPS Calculation [Table]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Total
Earnings Per Share, Basic, by Common Class, Including Two-Class Method [Table]
Debt conversion, number of shares issued
Pre-funded warrant shares
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Table]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Amortized Cost, as Adjusted
Gross Unrealized Holding Gains
Gross Unrealized Holding Losses
Estimated Fair Value
Total property and equipment, gross
Less: Accumulated depreciation
Total property and equipment, net
Depreciation expense
Employee compensation and benefits
License milestone
Interest
Consulting and professional fees
Other
Total
Accounts payable included accrued interest
2026
Thereafter
Total minimum lease payments
Less: Amount representing interest
Present value of operating lease liabilities
Less: operating lease liabilities, current
Weighted-average remaining lease term
Weighted-average discount rate
Operating lease cost
Variable lease cost
Total lease cost
Collaborative Arrangement and Arrangement Other than Collaborative [Table]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Square feet
Lease option to extend
Lease description
Initial annual lease payment
Undiscounted future minimum lease
Lease term
Non-cancelable contractual commitment
Issuance of common stock shares to Pfizer pursuant to an Equity Grant Agreement
Registration rights
Class of Warrant or Right [Table]
Class of Warrant or Right [Line Items]
Issue Date
Expiration Date
Number of Warrants Outstanding
Exercise Price
Offering
Accumulated Other Comprehensive Income (Loss) [Table]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Common stock warrants, outstanding shares
Weighted- average exercise price per share, outstanding
Common stock warrants, issued
Weighted- average exercise price per share, issued
Common stock warrants, exercised
Weighted- average exercise price per share, exercised
Common stock warrants, surrendered upon cashless exercise
Weighted- average exercise price per share, surrendered upon cashless exercise
Common stock warrants, expired
Weighted- average exercise price per share, expired
Common stock warrants, outstanding shares
Weighted- average exercise price per share, outstanding
Stock, Class of Stock [Table]
Class of Stock [Line Items]
Sale of stock
Share price
Prefunded warrant shares
Warrant purchase price
Class of warrant exercise price
The number of additional common stock shares the Underwriters can purchase
The cash inflow associated with the amount received from entity's offering of stock to the public
Pre-funded warrant exercisable description
Gross proceeds from public offering
Net proceeds from public offering
Gross proceeds
Commissions and other offering expenses
Pre-funded warrants sold to investors
Additional warrants exercised
Proceeds from warant exercise
Common stock warrants expired
Preferred stock voting rights
Common stock converted basis
Conversion of preferred to common stock, shares
Options outstanding at beginning of year
Options outstanding, weighted average exercise price at beginning of year
Options outstanding, weighted average remaining contractual term
Options outstanding, aggregate intrinsic value
Shares, Granted
Weighted Average Exercise Price, Granted
Shares, Exercised
Weighted Average Exercise Price, Exercised
Shares, Forfeited
Weighted Average Exercise, Forfeited
Options outstanding at end of year
Options outstanding, weighted average exercise price at end of year
Options outstanding, aggregate intrinsic value
Shares, options exercisable
Weighted Average Exercise Price, Options exercisable
Options exercisable, weighted average remaining contractual term
Options exercisable, aggregate intrinsic value
Risk-free interest rate, minimum
Risk-free interest rate, maximum
Expected volatility, minimum
Expected volatility, maximum
Expected life (years)
Expected dividend yield
Outstanding shares
Weighted-average grant date fair value per share, outstanding
Granted shares
Weighted-average grant date fair value per share, granted
Vested shares
Weighted-average grant date fair value per share, vested
Forfeited shares
Weighted-average grant date fair value per share, forfeited
Outstanding shares
Weighted-average grant date fair value per share, outstanding
StockBasedCompensationExpensesTable [Table]
StockBasedCompensationExpensesLineItem [Line Items]
Stock-based compensation expense
Number of shares reserved for issuance description
Change in common stock, shares reserved for issuance
Number of shares reserved for issuance, additional increases
Number of shares available for issuance
Option vested percentage
Option vested period
Stock based compensation expense related to modification
Remaining stock based compensation expense related to modification
Stock-based compensation expense
Weighted-average grant date fair value of options granted
Total intrinsic value of options exercised
Unrecognized compensation cost
Weighted-average period
Total fair value of restricted stock vested
Employee stock purchase plan description
Note payable
Add: Final fee
Add: PIK interest (added to principal)
Less: unamortized debt issuance costs
Less: unamortized debt discount
Total long-term debt
2028
2029
Total
Short-Term Debt [Table]
Short-Term Debt [Line Items]
Debt instrument principal amount
Net proceeds from offering
Conversion rate
Principal amount
Conversion price
Redemption description
Trading days
Consecutive trading days
First Amendment description
Fair value of the Notes
Discount amount
Interest rate
Interest expense
Discount amount
Disbursement loan amount
Contingent loan
Amendment fee payable
Net proceeds from loan
Debt final fee percentage
Funded loan amount
Warrants exercise price per share
Warrants issued
Debt Instrument, Fee Amount
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term
Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate
Maturity date
Conversion percentage
Common stock price per share
Amount of indebtedness eligible to incur under Term D Loan
Costs associated with new borrowings
Debt instrument interest rate description
Common stock price per share
Final fee percentage
Final fee
Warrant or right, reason for issuance, description
Fair value of warrants
Fair value of note payable
LicenseAgreementTable [Table]
Payment for upfront fees
Issuance of common stock shares to Pfizer pursuant to an Equity Grant Agreement
Aggregate value of milestone events
Payment on milestone event one
Research and development expense
Tax benefit at statutory rate
Tax benefit at statutory rate, percentage
State income tax benefit, net of federal tax effect
State income tax benefit, net of federal tax effect, percentage
Federal change in valuation allowance on deferred tax assets
Federal change in valuation allowance on deferred tax assets, percentage
Federal research and development credits
Federal research and development credits, percentage
Prior year adjustments
Prior year adjustments, percentage
Non-deductible items
Non-deductible items, percentage
Income tax expense (benefit)
Income tax expense (benefit), percentage
Accrued expenses
Stock-based compensation
Property and equipment
Right-of-use assets
Lease liabilities
Section 174 expenditures
Start-up expenditures
Net operating losses and tax credits
Deferred tax assets before valuation allowance
Valuation allowance
Net deferred tax assets
Effective Income Tax Rate Reconciliation [Table]
Effective Income Tax Rate Reconciliation [Line Items]
Income tax benefit
Federal net operating loss carryforwards
State net operating loss carryforwards
Tax credit carryforwards
Uncertain tax positions
Unrecognized tax benefits
Accrued interest or penalties
Subsequent Event [Table]
Subsequent Event [Line Items]
Aggregate offering amount
Conversion of preferred to common stock, shares.
Exercise of common stock warrants, net of shares withheld for exercise price, value.
Exercise of common stock warrants, net of shares withheld for exercise price, shares.
Stock issued during period value issuance upon closing of followon offering net of underwriting discounts and offering costs.
Stock issued during period shares issuance upon closing of followon offering net of underwriting discounts and offering costs.
Stock issued during period value issuance of common stock warrants in connection with note agreement.
Noncash operating lease expense net.
Change in accrued interest income.
Increase decrease in accrued clinical trial costs.
Payments for secondary registration statement costs.
Proceeds from atm offering net of issuance costs.
Deferred financing costs and offering and registration statement costs included in accounts payable.
Property and equipment included in accounts payable.
Common stock warrants issued with note payable transaction.
Accrued clinical trial costs.
Cash paid for operating leases.
Allowance For Credit Losses [Policy Text Block]
Schedule of Estimated Useful Lives of Property and Equipment [Table Text Block]
Licenses [Policy Text Block]
Patent Costs [Policy Text Block]
Recent Accounting Prononcement Adopted [Policy Text Block]
Prefunded warrant, shares.
Other accrued license milestone.
Other accrued interest.
Lessee operating lease liability payments due after year one.
Underwriting Agreement [Member]
July 2025 Equity Offering [Member]
Pre-Funded Warrants [Member]
Leerink Partners LLC [Member]
Proceeds from issuance of common stock net.
Open Market Sale Agreement [Member]
Jefferies LLC [Member]
Class of warrant or righst date from which warrants or rights issue.
Warrant One [Member]
Warrant Two [Member]
Warrant Three [Member]
Warrant Four [Member]
Warrant Five [Member]
Warrant Six [Member]
Warrant Seven [Member]
Warrant Eight [Member]
Warrant Nine [Member]
Warrant Ten [Member]
Warrant Eleven [Member]
Securities Purchase Agreement [Member]
Change in common stock, shares reserved for issuance
2017 Plan [Member]
Remaining stock based compensation expense related to modification.
Note Underwriting Agreement [Member]
July 2025 Convertible Notes Offering [Member]
Disbursement loan amount.
Amended and Restated Loan Agreement [Member]
Innovatus Life Sciences [Member]
Term D Loan [Member]
Term E Loan [Member]
Term E Two Loan [Member]
Term F Loan [Member]
Term F Two Loan [Member]
Term G Loan [Member]
Amendment fee.
Debt final fee percentage.
Third Amendment to Amended and Restated Loan and Security Agreement [Member]
Second Amendment To Amended And Restated Loan And Security Agreement [Member]
Loan Agreement [Member]
Term A Loan [Member]
Term B Loan [Member]
Term C Loan [Member]
Prior Loan Agreement [Member]
Final fee percentage.
Final fee.
Warrant or right, reason for issuance, description.
Payment in kind interest debt
License Agreement [Test Block]
Pfizer License Agreement [Member]
Aggregate value of milestone events
License Agreement [Member]
Payment on milestone event one.
2017 Employee Stock Purchase Plan [Member]
Deferred tax assets right of use assets.
Deferred tax assets lease liability.
Deferred tax assets tax deferred expense compensation and benefits IRC 174 expenditures.
Start-up expenditures
2012 Equity Incentive Plan [Member]
2017 Amended And Restated Stock Incentive Plan [Member]
Weighted- average exercise price per share, outstanding.
Weighted- average exercise price per share, issued.
Weighted- average exercise price per share, exercised.
Weighted- average exercise price per share, surrendered upon cashless exercise.
Weighted- average exercise price per share, expired.
Aggregate offering amount.
Options To Purchase Common Stock [Member]
Convertible Notes to Common Stock [Member]
Warrants To Purchase Common Stock [Member]
Preferred Stock On An As If Converted To Common Stock [Member]
Conversion of preferred stock to common stock value.
Conversion of preferred stock to common stock, shares
Senior Notes Due 2031 Notes [Member]
Statement of Income Location Balance [Axis]
Research and Development Expenses [Member]
General and Administrative Expenses [Member]
Research and development expense.
Assets, Current
Assets [Default Label]
Liabilities, Current
Liabilities
Equity, Attributable to Parent
Liabilities and Equity
Operating Expenses
Operating Income (Loss)
Interest Expense, Nonoperating
Nonoperating Income (Expense)
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest
Shares, Outstanding
ChangeInAccruedInterestIncome
Increase (Decrease) in Prepaid Expense
Increase (Decrease) in Other Current Assets
Increase (Decrease) in Accounts Payable
IncreaseDecreaseInAccruedClinicalTrialCosts
Increase (Decrease) in Other Accrued Liabilities
Cash Provided by (Used in) Operating Activity, Including Discontinued Operation
Payments to Acquire Investments
Payments to Acquire Property, Plant, and Equipment
Cash Provided by (Used in) Investing Activity, Including Discontinued Operation
PaymentsForSecondaryRegistrationStatementCosts
Cash Provided by (Used in) Financing Activity, Including Discontinued Operation
Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Excluding Exchange Rate Effect, Including Discontinued Operation
Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Including Discontinued Operation
Forgone Recovery, Individual Name
Outstanding Recovery, Individual Name
Awards Close in Time to MNPI Disclosures, Individual Name
Trading Arrangement, Individual Name
Rule 10b5-1 Arrangement Terminated [Flag]
Non-Rule 10b5-1 Arrangement Terminated [Flag]
Investment [Text Block]
License Agreement [Test Block]
Investment, Policy [Policy Text Block]
Property, Plant and Equipment, Policy [Policy Text Block]
Share-Based Payment Arrangement [Policy Text Block]
Income Tax, Policy [Policy Text Block]
Cash Equivalents, at Carrying Value
Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment
Other Accrued Liabilities, Current
Lessee, Operating Lease, Liability, to be Paid
Lease, Cost
Warrants and Rights Outstanding, Maturity Date
Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding, Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsNonOptionsWeightedAverageGrantDateFairValue
Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Exercised
Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Other
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period
Share-Based Payment Arrangement, Expense
Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net
Long-Term Debt
Amortization of Debt Discount (Premium)
Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount
Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent
Effective Income Tax Rate Reconciliation, Percent
Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost
DeferredTaxAssetsLeaseLiability
Deferred Tax Assets, Gross
Deferred Tax Assets, Valuation Allowance
Deferred Tax Assets, Net